Main Menu
Menu

Nick Robertson

Publish Date
News
US Senate continues uphill battle on patent eligibility bill
MLex
Resources
Letters
C4IP Letter to Senate Judiciary IP Subcommittee on PERA Hearing
Resources
Public Comments
C4IP Comments RE: U.K. IPO Consultation on SEPs
News
How impactful is the new USPTO director’s S101 decision?
WIPR
Blog
Inventor Spotlight: John B. Goodenough

This month, C4IP is honoring John B. Goodenough (1922-2023), whose work on the invention of the lithium-ion battery powers billions of high-tech...

Blog
Why C4IP Supports the Patent Eligibility Restoration Act of 2025 (PERA)

This chaotic area of law harms American innovation and competitiveness Without Congressional consideration or endorsement, the Supreme Court has fundamentally altered the...

Fact ChecksResources
Infographics & Fact Sheets
Myths vs. Facts: The Patent Eligibility Restoration Act (PERA) – Software and Technology

The Patent Eligibility Restoration Act of 2025 (PERA), sponsored by Sens. Thom Tillis (R-NC) and Chris Coons (D-DE), is bipartisan legislation that...

Fact ChecksResources
Infographics & Fact Sheets
Myths vs. Facts: The Patent Eligibility Restoration Act (PERA) – Diagnostics and Life Sciences

The Patent Eligibility Restoration Act of 2025 (PERA), sponsored by Sens. Thom Tillis (R-NC) and Chris Coons (D-DE), is bipartisan legislation that...

News
Amgen Attacks Academics’ False Claims About Biologic Patents
IPWatchdog
News
C4IP Publishes Website Addressing Misinformation Published by I-MAK
IPWatchdog
BlogFact Checks
Fact Check: Separating Fact From Fiction in Recent FTC/DOJ Listening Sessions on Patents in the Drug Industry

Myths about how patent rights affect competition within the drug industry remain a pressing issue for innovators. Although strong patents play a...

Press Releases
Council for Innovation Promotion Publishes New Website Addressing I-MAK Myths

WASHINGTON (September 18, 2025) — Today, the Council for Innovation Promotion (C4IP) launched www.I-MAKexposed.com, a new website to combat the patent misinformation...

News:

News:

US Senate continues uphill battle on patent eligibility bill,

10/07/2025
Resources:

Resources:

C4IP Letter to Senate Judiciary IP Subcommittee on PERA Hearing,

10/07/2025
Resources:

Resources:

C4IP Comments RE: U.K. IPO Consultation on SEPs,

10/03/2025
News:

News:

How impactful is the new USPTO director’s S101 decision?,

10/02/2025
Blog:

Blog:

Inventor Spotlight: John B. Goodenough,

09/26/2025
Blog:

Blog:

Why C4IP Supports the Patent Eligibility Restoration Act of 2025 (PERA),

09/25/2025
Resources:

Fact Checks, Resources:

Myths vs. Facts: The Patent Eligibility Restoration Act (PERA) – Software and Technology,

09/25/2025
Resources:

Fact Checks, Resources:

Myths vs. Facts: The Patent Eligibility Restoration Act (PERA) – Diagnostics and Life Sciences,

09/25/2025
News:

News:

Amgen Attacks Academics’ False Claims About Biologic Patents,

09/21/2025
News:

News:

C4IP Publishes Website Addressing Misinformation Published by I-MAK,

09/19/2025
Blog:

Blog, Fact Checks:

Fact Check: Separating Fact From Fiction in Recent FTC/DOJ Listening Sessions on Patents in the Drug Industry,

09/19/2025
Press Releases:

Press Releases:

Council for Innovation Promotion Publishes New Website Addressing I-MAK Myths,

09/18/2025
Scroll to Top